Celldex Therapeutics (CLDX) said Wednesday that the first patient has been dosed in the company's phase 1a study of CDX-622, a potential inflammatory disease treatment, in healthy volunteers.
The drug is an antibody that targets two complementary pathways that drive inflammatory diseases by neutralizing thymic stromal lymphopoietin and depleting mast cells, the company said.
The phase 1a study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses and multiple ascending doses of CDX-622 in up to 56 healthy participants, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。